Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239921 | 0.83 | KDM4E (0.55) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL10130562 | 0.79 | KDM4E (0.58) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL13615811 | 0.78 | IDH1 (0.43) | KDM4EMAPTTRPM8ALDH1A1LOXL2 | |
| SCHEMBL10130634 | 0.76 | KDM4E (0.59) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL19143309 | 0.76 | KDM4E (0.61) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL24958732 | 0.75 | KDM4E (0.57) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL20809152 | 0.74 | KDM4E (0.61) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL13437308 | 0.73 | ALDH1A1 (0.50) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL3229697 | 0.73 | CES1 (0.65) | KDM4ENPC1MAPTRAB9AGLA | |
| SCHEMBL10260862 | 0.71 | CYP1A2 (0.50) | KDM4ETRPM8POLBLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | KDM4E 523/4885NPC1 77/4885MAPT 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.